Nucleobases Found on Asteroid Ryugu, Glucose-to-Gluconate Diabetes Implant, KCL-286 Targets Upstream of Amyloid, Lacosamide for Knee Arthritis, Microplastic ROS Generation, and Endometrial Cancer Swab Test

Broadcast from KSQD, Santa Cruz on 11-05-2026:

• Japan's Hayabusa2 mission returned 5 grams of pristine samples from asteroid Ryugu in contamination-proof conditions, and analysis found all five of the nucleobases that form the letters of DNA and RNA (pyrimidines and purines)—replicating a 2025 NASA result and strengthening the case that genetic-material building blocks may originate in space.
• A Swiss research group developed a graphite-felt implant studded with gold nanoclusters coated in platinum particles that catalytically oxidizes glucose to gluconate, a waste product eliminated in urine rather than stored as fat. Wirelessly powered through a continuous glucose monitor and smartphone, the device activates only when blood sugar rises too high. Experimental diabetic mice lost weight and their blood sugar. This new invention addresses the excess-energy problem that insulin alone leaves untouched.
• King's College London researchers identified KCL-286,as a promising Alzheimer's candidate that works upstream of the beta-amyloid and tau deposits that dominated three decades of failed drug development. KCL-286 was originally developed for spinal cord injury and has already passed phase-one human safety trials. The orally bioavailable small molecule activates a retinoic acid pathway protein that repairs DNA double-strand breaks and reduces inflammation—the actual early drivers of non-hereditary Alzheimer's.
• Dr. Dawn riffs on "type 3 diabetes," the functional medicine framing for high-glucose brain inflammation driving dementia. She emphasizes the disturbing statistic that poor blood sugar control epidemiologically subtracts about 10 years from dementia-free lifespan.
  /li>

• Yale researchers found the approved epilepsy drug lacosamide blocks a sodium channel that is unusually active in osteoarthritic chondrocytes, where it drives both pain signaling and cartilage destruction. Injected monthly in a temperature-responsive collagen type 2 hydrogel that gels at body heat to keep the drug in the joint, lacosamide reduced pain, encouraged cartilage-building proteins, and suppressed tissue breakdown, greatly outperforming daily oral dosing.
• A caller asks about newly prescribed alendronate and oyster-shell calcium for osteoporosis; Dr. Dawn explains alendronate cross-links bone calcium so osteoclasts can't easily break it down, slowing fractures—but also slowing dental implant and joint-replacement healing, with rare atypical femur fractures after years of use (drug holidays help). The weekly alendronate dosing instructions require an empty stomach and staying upright for an hour after dosing to avoid esophageal damage.
• Columbia researchers published in Nature that microplastics in water generate reactive oxygen species via interfacial electrostatics, overturning the assumption that only weathered plastic poses harm. A credit-card-sized plastic broken into microplastics increases surface area 1000-fold, with brand-new unweathered plastic generating ROS just as actively—damaging DNA, proteins, and cell membranes. Microplastics are known to produce Alzheimer's-like symptoms and atherosclerosis in mice at massive doses.
• A new vaginal swab (PinkDx) detects shed DNA and RNA fragments from endometrial cancers of the uterus with claimed 90% sensitivity and 50% specificity. Potentially helping some women avoid biopsy.
• Dr. Dawn argues for earlier (pre-65) DEXA bone scans and short-course hormone replacement at menopause onset, since 30% of lifetime bone loss can occur in the first two years before periods even completely stop. Walk-in DEXA scans run $119 at mobile services versus $600 at hospitals.